AU534051B2 - Ergot alkaloid slow-release compositions - Google Patents

Ergot alkaloid slow-release compositions

Info

Publication number
AU534051B2
AU534051B2 AU54031/79A AU5403179A AU534051B2 AU 534051 B2 AU534051 B2 AU 534051B2 AU 54031/79 A AU54031/79 A AU 54031/79A AU 5403179 A AU5403179 A AU 5403179A AU 534051 B2 AU534051 B2 AU 534051B2
Authority
AU
Australia
Prior art keywords
slow
release compositions
ergot alkaloid
ergot
alkaloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54031/79A
Other languages
English (en)
Other versions
AU5403179A (en
Inventor
Joachim Franz
Ludwig Patt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of AU5403179A publication Critical patent/AU5403179A/en
Application granted granted Critical
Publication of AU534051B2 publication Critical patent/AU534051B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU54031/79A 1978-12-21 1979-12-19 Ergot alkaloid slow-release compositions Ceased AU534051B2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CH1302178 1978-12-21
CH1301978 1978-12-21
CH1301978 1978-12-21
CH1302178 1978-12-21
CH56779 1979-01-19
CH56679 1979-01-19
CH56679 1979-01-19
CH56779 1979-01-19

Publications (2)

Publication Number Publication Date
AU5403179A AU5403179A (en) 1980-06-26
AU534051B2 true AU534051B2 (en) 1984-01-05

Family

ID=27427929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54031/79A Ceased AU534051B2 (en) 1978-12-21 1979-12-19 Ergot alkaloid slow-release compositions

Country Status (23)

Country Link
AT (1) AT372279B (fr)
AU (1) AU534051B2 (fr)
CA (1) CA1139222A (fr)
CH (1) CH642259A5 (fr)
CY (1) CY1330A (fr)
DE (1) DE2950154A1 (fr)
DK (1) DK154607C (fr)
FI (1) FI793888A (fr)
FR (1) FR2444463A1 (fr)
GB (1) GB2038181B (fr)
HK (1) HK37986A (fr)
HU (1) HU182577B (fr)
IE (1) IE49323B1 (fr)
IL (1) IL59003A (fr)
IT (1) IT1164029B (fr)
KE (1) KE3617D (fr)
MY (1) MY8500129A (fr)
NL (1) NL187229C (fr)
NZ (1) NZ192457A (fr)
PH (1) PH25178A (fr)
PT (1) PT70614A (fr)
SE (1) SE442265B (fr)
WO (1) WO1980001242A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3264867D1 (en) * 1981-04-27 1985-08-29 Haessle Ab New pharmaceutical preparation
US4366145A (en) * 1981-06-24 1982-12-28 Sandoz, Inc. Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation
HU192050B (en) * 1983-04-22 1987-05-28 Sandoz Ag Process for production of medical preparative containing co-dergocrin and one piridin-dicarbonic acid diesthertype calcium-antagonist
DE3413955A1 (de) * 1983-04-22 1984-10-25 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutisches praeparat enthaltend co-dergocrine und einen calcium-antagonisten
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
GB8426922D0 (en) * 1984-10-24 1984-11-28 Sandoz Ltd Galenic formulation
AT388101B (de) * 1985-02-05 1989-05-10 Sandoz Ag Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur oralen verabreichung mit kontrollierter wirkstofffreisetzung
CN1003978B (zh) * 1987-09-05 1989-04-26 广州陈李济药厂 一种补脾益肠丸的制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
DE2528257C2 (de) * 1974-07-04 1986-02-13 Sandoz-Patent-GmbH, 7850 Lörrach Neue galenische Zubereitung
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden

Also Published As

Publication number Publication date
MY8500129A (en) 1985-12-31
DK529879A (da) 1980-06-22
IL59003A (en) 1982-12-31
NL7909105A (nl) 1980-06-24
GB2038181A (en) 1980-07-23
IE49323B1 (en) 1985-09-18
NL187229C (nl) 1991-07-16
SE442265B (sv) 1985-12-16
IT7951153A0 (it) 1979-12-20
CY1330A (en) 1986-06-27
GB2038181B (en) 1983-05-11
WO1980001242A1 (fr) 1980-06-26
PT70614A (fr) 1980-01-01
AT372279B (de) 1983-09-26
FR2444463A1 (fr) 1980-07-18
DE2950154C2 (fr) 1989-05-11
FR2444463B1 (fr) 1983-02-25
NZ192457A (en) 1983-06-17
IE792471L (en) 1980-06-21
CA1139222A (fr) 1983-01-11
AU5403179A (en) 1980-06-26
DK154607C (da) 1989-06-05
CH642259A5 (de) 1984-04-13
SE7910227L (sv) 1980-06-22
DE2950154A1 (de) 1980-07-10
HK37986A (en) 1986-05-30
HU182577B (en) 1984-02-28
DK154607B (da) 1988-12-05
IT1164029B (it) 1987-04-08
KE3617D (en) 1986-04-18
ATA803679A (de) 1983-02-15
PH25178A (en) 1991-03-27
FI793888A (fi) 1980-06-22

Similar Documents

Publication Publication Date Title
AU520754B2 (en) Nasal ergot alkaloid compositions
AU536181B2 (en) Derivatives of camptothecin
AU4551179A (en) Polymer-polyol compositions
AU4344579A (en) Nitro-bromo-alkanol compositions
AU529805B2 (en) Xanthine compositions
AU524193B2 (en) Clavulanic acid composition
AU508628B2 (en) Ergot alkaloid compositions
AU526938B2 (en) Eva composition
AU526954B2 (en) Penicillin composition
AU537581B2 (en) Ergoline derivatives
AU534051B2 (en) Ergot alkaloid slow-release compositions
GB2056279B (en) Dermatological compositions containing alkaloids
AU540812B2 (en) Steroid alkaloids
AU523773B2 (en) Benzodiazepine compositions
AU545645B2 (en) Ergot alkaloid
AU530738B2 (en) Fasciolicidal compositions
AU530974B2 (en) Phosphoranyl nitrogen derivatives
AU525818B2 (en) Ergot peptide alkaloid derivates
AU531211B2 (en) Nalbuphine composition
AU4691379A (en) Vinca alkaloids
AU6302180A (en) Ergot alkaloid
HK81085A (en) Pharmaceutical compositions containing an ergot alkaloid and heparin
AU512782B2 (en) Compositions comprising heparin andan ergot alkaloid
AU529462B2 (en) Bromination of ergot alkaloids
AU6468980A (en) Ergoline derivatives